Chugai Pharmaceutical struck a global license and collaboration with Rani Therapeutics to develop an oral formulation that pairs Rani’s Ranipill robotic delivery with Chugai’s rare‑disease antibody program. Financial terms approach $1 billion and cover development and commercialization rights worldwide. The agreement aims to convert injectable biologics into an oral product, a strategic push to expand patient access for chronic rare disease therapies.